cas 216959-87-4|| where to buy 4-(triazol-1-yl)benzoic acid

Nom du produit:4-(triazol-1-yl)benzoic acid

IUPAC Name:4-(1H-1,2,3-triazol-1-yl)benzoic acid

Unité d'emballage	Stock disponible	Prix($)
CM751086-1g	in stock	ǎǎ
CM751086-5g	in stock	Łřǟ
CM751086-25g	in stock	ƏƏŽƴ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 216959-87-4 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:216959-87-4; Formule moléculaire:C9H7N3O2; Point de fusion:-; Code SMILES:OC(=O)C1=CC=C(C=C1)N1C=CN=N1; Densité:

: Numéro de catalogue:CM751086; Poids moléculaire:189.17; Point d'ébullition:; N° Mdl:MFCD20483616; Stockage:

: Triazoles; Triazole refers to a heterocyclic compound with the molecular formula C2H3N3, which has a five-membered ring consisting of two carbon atoms and three nitrogen atoms. Neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease already affect many people around the world, and these numbers are increasing rapidly. Treatment for these disorders is often aimed at relieving symptoms and has no cure. Research on new molecules is underway, and heterocyclic compounds have important pharmacological implications. Triazoles and tetrazoles are emerging as new molecules in this field.

: Bomedemstat; Merck recently announces the initiation of the pivotal Phase 3 randomized MK-3543-006 clinical trial of Bomedemstat for Essential Thrombocythemia (ET). Lysine-specific demethylase 1 (LSD1) is critical for the regulation of hematopoietic stem and progenitor cells. Bomedemstat is an investigational small molecule irreversible inhibitor of LSD1 by suppressing progenitor cells during blood cell maturation. It is generally well tolerated in ET patients and demonstrates significant clinical activity as a monotherapy.
Bomedemstat has been granted Orphan Drug and Fast Track Designation for the treatment of ET and myelofibrosis (MF) by the U.S. FDA.